In male Sprague-Dawley rats, Rasagiline administered by gavage before and during rotenone treatment ameliorated cataleptic behavior compared with the rotenone-only model group. In CD157 KO mice, a single subcutaneous administration of Rasagiline reduced FST immobility time compared with saline-treated mice. In male C57/Bl6 mice, intraperitoneal Rasagiline pretreatment did not restore dopamine metabolite levels in the presence of MPTP and further decreased DOPAC and HVA levels. [2,3,1]
Rasagiline and rotenone-induced cataleptic behavior in rats
Animal study · Male Sprague-Dawley rats [2]
Male Sprague-Dawley rats received Rasagiline by gavage before co-treatment with rotenone. Rasagiline ameliorated rotenone-induced cataleptic behavior compared with the rotenone-only model group.
Conditions shared by the study groups
- Route
- gavage
- Treatment course
- Rats in group 7 received rasagiline for 10 days and were then co-treated with rotenone for 4 weeks. During a 4-week co-treatment period in groups 1 and 4-7, saline, different doses of fucoidan and rasagiline were administrated once a day, while rotenone and DMSO + sunflower oil were given 5 times a week.
- Vehicle
- 0.5% hydroxypropyl methyl cellulose
- Rasagiline 0.3 mg/kg
- Model: Male Sprague-Dawley rats
Methods and source locations
Compound reported in the paper: Rasagiline
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
MATERIALS AND METHODS > Animals (S7); MATERIALS AND METHODS > Experimental design (S14, S16, S17, S18, S20); MATERIALS AND METHODS > In situ studies of mitochondrial respiratory function (S87, S88); RESULTS > Effects of fucoidan on catalepsy in PD rats (S115, S119)
descent latency in the bar (Fig. 2A) and grid test (Fig. 2B): descent latency in the bar (Fig. 2A) and grid test (Fig. 2B); comparator: model group (rotenone only) — MATERIALS AND METHODS > In situ studies of mitochondrial respiratory function (S87); RESULTS > Effects of fucoidan on catalepsy in PD rats (S115, S119)
Rasagiline 0.3 mg/kg · MATERIALS AND METHODS > Experimental design (S16, S17, S20); MATERIALS AND METHODS > In situ studies of mitochondrial respiratory function (S87); RESULTS > Effects of fucoidan on catalepsy in PD rats (S119)
Rasagiline and immobility in knockout mice
Animal study · CD157 KO mice [3]
CD157 KO mice received a single subcutaneous injection of Rasagiline. Rasagiline reduced immobility time in the FST compared with saline-treated CD157 KO mice.
Conditions shared by the study groups
- Route
- s.c. injection
- Treatment course
- single s.c. injection; 1 h after the last injection
- Vehicle
- saline
- Rasagiline 1 or 10 mg/kg
- Model: CD157 KO mice
Methods and source locations
Compound reported in the paper: Rasagiline
Evidence for Rasagiline as the mesylate form reported in the paper, not the free base/neutral form supplied as A11111; no salt equivalence, dose conversion or lot validation.
Materials and Methods > Drugs (S10, S14); Materials and Methods > Forced Swimming Test (FST) (S16); Figure 1 legend (S111)
total duration of immobility during the last 4 min of the test: total duration of immobility during the last 4 min of the test; comparator: saline-treated CD157 KO mice — Materials and Methods > Forced Swimming Test (FST) (S16); Figure 1 legend (S111)
Rasagiline 1 or 10 mg/kg · Materials and Methods > Drugs (S10, S14); Figure 1 legend (S111)
Rasagiline and dopamine metabolite levels during MPTP treatment
Animal study · male C57/Bl6 mice [1]
Male C57/Bl6 mice received a single intraperitoneal pretreatment with Rasagiline before MPTP treatment. In the presence of MPTP, Rasagiline did not restore dopamine metabolite levels and further decreased DOPAC and HVA levels.
Conditions shared by the study groups
- Route
- i.p.
- Treatment course
- a single i.p. pretreatment; 18 h before the start of MPTP treatment; 72 h after the last MPTP treatment
- Rasagiline 10 mg/kg
- Model: male C57/Bl6 mice
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Rasagiline
Evidence for Rasagiline as the mesylate form reported in the paper, not the free base/neutral form supplied as A11111; no salt equivalence, dose conversion or lot validation.
Results > The protective effect of the compounds in acute MPTP-induced striatal dopamine depletion and motor deficit in mice (S20, S21, S34); Methods > In vivo acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model (S138, S139); Fig. 4 legend (S268, S271)
endogenous dopamine metabolite (DOPAC, HVA) levels: endogenous dopamine metabolite (DOPAC, HVA) levels; comparator: MPTP treated — Results > The protective effect of the compounds in acute MPTP-induced striatal dopamine depletion and motor deficit in mice (S34); Fig. 4 legend (S268)
Rasagiline 10 mg/kg · Results > The protective effect of the compounds in acute MPTP-induced striatal dopamine depletion and motor deficit in mice (S20, S21, S34); Methods > In vivo acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model (S139)